Seres Therapeutics rises on 'breakthrough therapy' tag for blood infection treatment

Seres Therapeutics

09/12/2024 14:17

** Shares of drug developer Seres Therapeutics  MCRB.O  rise
14.1% to 93 cents premarket
    ** Says the U.S. FDA has granted "Breakthrough Therapy"
designation to its experimental treatment, SER-155
    ** The treatment helps reduce bloodstream infections in
adults undergoing allogeneic hematopoietic stem cell transplant
to treat various types of blood cancers
    ** The transplant uses blood stem cells from a donor to
replace bone marrow that's not producing enough healthy blood
cells
    ** SER-155 was well-tolerated with no treatment-related
serious adverse events in an early-stage study - MCRB
    ** The FDA's tag is meant to speed up development and review
of drugs to treat a serious condition or unmet medical need
    ** Co is actively seeking a partner to provide financial
resources and other capabilities to support its  goal to
maximize the SER-155 program opportunity
    ** Up to last close, stock down 41.2% YTD

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))